ARTICLE | Company News

Myriad Genetics, German Consortium for Hereditary Breast and Ovarian Cancer deal

January 23, 2012 8:00 AM UTC

Myriad received an exclusive, worldwide license from the consortium to IP covering the use of RAD51C gene to assess a patient's predisposition for hereditary breast and ovarian cancer. The license is co-exclusive to Myriad and the consortium in Germany, and exclusive to Myriad elsewhere worldwide. Terms were not disclosed. ...